摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-ethoxy-2-methyl-4H-pyran-4-one

中文名称
——
中文别名
——
英文名称
3-ethoxy-2-methyl-4H-pyran-4-one
英文别名
ethyl maltol;3-ethoxy-2-methylpyran-4-one
3-ethoxy-2-methyl-4H-pyran-4-one化学式
CAS
——
化学式
C8H10O3
mdl
——
分子量
154.166
InChiKey
XKGZTJGVEGDXJR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-ethoxy-2-methyl-4H-pyran-4-one 作用下, 以 乙醇 为溶剂, 反应 24.0h, 以95%的产率得到3-ethoxy-2-methylpyridin-4(1H)-one
    参考文献:
    名称:
    WO2007/120098
    摘要:
    公开号:
  • 作为产物:
    描述:
    麦芽醇碘乙烷sodium hydroxide 作用下, 以 甲醇 为溶剂, 以71%的产率得到3-ethoxy-2-methyl-4H-pyran-4-one
    参考文献:
    名称:
    WO2007/120098
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and β-amyloid aggregation inhibitors for the treatment of Alzheimer’s disease
    作者:Minkui Zhang、Li Tang、Liu Jiang、Jun Wei、Yongzhou Hu、Rong Sheng
    DOI:10.1016/j.ejmech.2020.113096
    日期:2021.2
    functional agents for therapy of Alzheimer’s disease, through introducing alkyloxy moiety into 4-pyridinone ring to avoid the possible phase II metabolism of 3-hydroxy-4-pyridinone in lead compound 3-hydroxy-2-methyl-1-(4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-pyridin-4(1H)-one (4). In vitro studies indicated that most of these compounds exhibit excellent H3 receptor antagonistic activities and potent
    根据我们以前的工作,通过将烷氧基部分引入4-吡啶酮环中以避免可能的II期,设计了一系列N-苯基-3-甲氧基-4-吡啶酮衍生物作为口服生物可利用的双重功能药物,用于治疗阿尔茨海默氏病铅化合物的3-羟基-4-吡啶酮的代谢3-羟基-2-甲基-1-(4-(3-(吡咯烷-1-基)丙氧基)苯基) -吡啶-4-(1 ħ) -酮( 4)。体外研究表明,这些化合物大多数都具有出色的H 3受体拮抗活性和强力的自诱导Aβ1-40 / Aβ1-42聚集抑制活性。特别是,3-甲氧基-1-(4-(3-(吡咯烷基-1-基)丙氧基)苯基)-吡啶-4(1H)-一(7i)在H 3 R拮抗作用中显示IC 50值为0.52 nM。对其他组胺受体亚型具有良好的选择性。透射电子显微镜(TEM)图像显示化合物7i可有效抑制自我介导的Aβ1-40 / Aβ1-42聚集。如预期的那样,它在血浆中表现出理想的药代动力学性质和良好的BBB渗透
  • SUBSTITUTED QUINONES OR ANALOGUES AS COLOURING AGENTS
    申请人:MERCK PATENT GMBH
    公开号:US20150315177A1
    公开(公告)日:2015-11-05
    The invention relates to protein-adhesive dyes, to the preparation thereof and to preparations comprising same, and to a method for colouring keratin-containing fibres, in particular for colouring human hair.
    本发明涉及蛋白质黏合染料及其制备和制备物,以及一种用于着色含角蛋白纤维的方法,特别是用于着色人类头发的方法。
  • Thioxanthine derivatives and their use as inhibitors of MPO
    申请人:AstraZeneca AB
    公开号:US08026244B2
    公开(公告)日:2011-09-27
    There are disclosed novel compounds of Formula (I) wherein L, R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.
    本发明涉及一种新型化合物的公开,其化学式为(I),其中L、R1、X和Y如规范中所定义,并且其药学上可接受的盐;以及它们的制备方法、含有它们的组合物和它们在治疗中的应用。这些化合物是MPO酶的抑制剂,因此特别适用于治疗或预防神经炎症性疾病、心脏和脑血管动脉粥样硬化性疾病、周围动脉疾病和呼吸系统疾病。
  • Thioxanthine Derivatives and Their Use as Inhibitors of MPO
    申请人:Tiden Anna-Karin
    公开号:US20090149475A1
    公开(公告)日:2009-06-11
    There are disclosed novel compounds of Formula (I) wherein L, R 1 , X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.
    本发明公开了新的化合物式(I),其中L、R1、X和Y如规范中所定义,并且其药学上可接受的盐;以及其制备方法、含有它们的组合物和它们在治疗中的应用。这些化合物是MPO酶的抑制剂,因此在神经炎症性疾病、心血管和脑血管动脉粥样硬化性疾病、周围动脉疾病和呼吸系统疾病的治疗或预防中特别有用。
  • FLAVOR COMPOSITION OR FRAGRANCE COMPOSITION, AND FLAVOR-IMPROVING AGENT
    申请人:Takasago International Corporation
    公开号:EP1944354A1
    公开(公告)日:2008-07-16
    The present invention relates to a flavor composition or fragrance composition which can satisfy diversified requirements for flavored products, as well as to a flavor-improving agent which can improve the quality and release of aroma of a beverage or food. More particularly, the present invention relates to a flavor composition or fragrance composition which comprises an optically active S-alkyl 2-methylbutanethioate as an active ingredient, a flavor- or fragrance-added product, a flavor-improving agent which comprises an optically active S-alkyl 2-methylbutanethioate as an active ingredient, and a beverage or food having an improved flavor. The optically active S-alkyl 2-methylbutanethioate includes S-alkyl (R)-2-methylbutanethioate and S-alkyl (S)-2-methylbutanethioate.
    本发明涉及一种能够满足风味产品多样化要求的风味组合物或香味组合物,以及一种能够改善饮料或食品的品质和香气释放的风味改进剂。更具体地说,本发明涉及一种由光学活性 S-烷基 2-甲基硫代丁酸酯作为活性成分的香精组合物或香料组合物、一种添加香精或香料的产品、一种由光学活性 S-烷基 2-甲基硫代丁酸酯作为活性成分的风味改进剂以及一种具有改进风味的饮料或食品。光学活性 S-烷基 2-甲基硫代丁酸酯包括 S-烷基 (R)-2-甲基硫代丁酸酯和 S-烷基 (S)-2-甲基硫代丁酸酯。
查看更多